Is NeuroPace, Inc. overvalued or undervalued?

As of 3 June 2021, the valuation grade for NeuroPace, Inc. moved from does not qualify to risky, indicating a shift in the perception of its financial health. The company is currently assessed as overvalued given its significant negative ratios, including a Price to Book Value of 17.77 and an EV to EBITDA of -28.78. Additionally, the Return on Capital Employed (ROCE) stands at a concerning -97.74%, and the Return on Equity (ROE) is at -102.91%, suggesting severe operational inefficiencies.
In comparison to its peers, NeuroPace's P/E ratio is at -14.16, while AngioDynamics, Inc. has a P/E of -21.90 and Sanara MedTech, Inc. at -18.73, all indicating a challenging environment for profitability. The company's recent stock performance has also lagged behind the S&P 500, with a year-to-date return of -5.54% compared to the index's 2.44%. Overall, these indicators suggest that NeuroPace, Inc. is overvalued in the current market context.